0001209191-21-065223.txt : 20211117
0001209191-21-065223.hdr.sgml : 20211117
20211117180842
ACCESSION NUMBER: 0001209191-21-065223
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20211115
FILED AS OF DATE: 20211117
DATE AS OF CHANGE: 20211117
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Thomsen Jillian B.
CENTRAL INDEX KEY: 0001433457
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-24006
FILM NUMBER: 211421843
MAIL ADDRESS:
STREET 1: C/O NEKTAR THERAPEUTICS
STREET 2: 201 INDUSTRIAL ROAD
CITY: SAN CARLOS
STATE: CA
ZIP: 94070
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: NEKTAR THERAPEUTICS
CENTRAL INDEX KEY: 0000906709
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 943134940
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 455 MISSION BAY BOULEVARD SOUTH
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
BUSINESS PHONE: 4154825300
MAIL ADDRESS:
STREET 1: 455 MISSION BAY BOULEVARD SOUTH
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94158
FORMER COMPANY:
FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS INC
DATE OF NAME CHANGE: 19980723
FORMER COMPANY:
FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS
DATE OF NAME CHANGE: 19940303
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-11-15
0
0000906709
NEKTAR THERAPEUTICS
NKTR
0001433457
Thomsen Jillian B.
C/O NEKTAR THERAPEUTICS
455 MISSION BAY BOULEVARD SOUTH
SAN FRANCISCO
CA
94158
0
1
0
0
SVP & Chief Accounting Officer
Common Stock
2021-11-15
4
A
0
14900
0.00
A
152722
D
Common Stock
2021-11-16
4
S
0
6741
13.16
D
145981
D
Common stock was acquired pursuant to a grant of restricted stock units ("RSU"). Each RSU awarded represents a contingent right to receive, upon vesting of the unit, one share of Common Stock of the Issuer. These RSUs were granted on December 12, 2019 under the Issuer's Amended and Restated 2017 Performance Incentive Plan (the "2017 Plan") and at the time of their grant were subject to both performance-based and time-based vesting requirements. The time-based vesting is on a quarterly pro-rata basis over a period of three (3) years from the date of grant.
The Organization and Compensation Committee of the Board of Directors of the Issuer determined that the performance-based vesting requirement for these RSUs was satisfied on September 15, 2021. Pursuant to the terms of the 2017 Plan, these RSUs vested on the next quarterly vesting date (November 15, 2021) following the date that the performance-based vesting requirement was satisfied.
This number includes 988 shares held by the reporting person in the Issuer's 401(K) plan and 5,690 shares held by the reporting person in the Issuer's ESPP plan. The acquisition of these shares under both plans is exempt under Rule 16b-3(c).
Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the RSUs held by the reporting person. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
This transaction was executed in multiple trades at prices ranging from $12.84 to $13.52. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon request to the SEC staff, the Issuer, or a security holder of the Issuer.
Mark A. Wilson
2021-11-17